CervoMed Inc 8-K, filed Feb 6, 2020
CervoMed Inc. (CRVO)
About this 8-K
CervoMed Inc filed this 8-K on February 6, 2020, reporting on events of February 2, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 2 , 2020
DIFFUSION PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-24477 | 30-0645032 |
|---|---|---|
| (State or other jurisdiction of<br><br> <br>incorporation) | (Commission File<br><br> <br>Number) | (I.R.S. Employer<br><br> <br>Identification No.) |
| 1317 Carlton Avenue, Suite 200<br><br> <br>Charlottesville, Virginia | 22902 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
(434) 220-0718
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | DFFN | NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|---|
(b) On February 2, 2020, John L. Gainer, Ph.D. notified Diffusion Pharmaceuticals Inc. (the “Company”) of his intent to resign, effective March 12, 2020, as Chief Scientific Officer of the Company. Dr. Gainer remains a member of the Company’s Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: February 6, 2020 | DIFFUSION PHARMACEUTICALS INC. | |
|---|---|---|
| By: | /s/ David G. Kalergis | |
| Name: | David G. Kalergis | |
| Title: | Chief Executive Officer |